Metabolic syndrome is defined as a cluster of glucose intolerance, hypertension, dyslipidemia and central obesity with insulin resistance as the source of pathogenesis. Although several different combinations of criteria have been used to define metabolic syndrome, a recently published consensus recommends the use of ethnic-specific criteria, including waist circumference as an indicator of central obesity, triglyceride and high-density lipoprotein (HDL) cholesterol as indicators of dyslipidemia, and blood pressure greater than 130/85 mmHg. The definition of dysglycemia, and whether central obesity and insulin resistance are essential components remain controversial. Regardless of the definition, the prevalence of metabolic syndrome is increasing in Western and Asian countries, particularly in developing areas undergoing rapid socioenvironmental changes. Numerous clinical trials have shown that metabolic syndrome is an important risk factor for cardiovascular disease (CVD), type 2 diabetes mellitus and all-cause mortality. Therefore, metabolic syndrome might be useful as a practical tool to predict these two major metabolic disorders. Comprehensive management of risk factors is very important to the improvement of personal and public health. However, recent studies have focused on the role metabolic syndrome plays as a risk factor for CVD; its importance in the prediction of incident diabetes is frequently overlooked. In the present review, we summarize the known evidence supporting metabolic syndrome as a predictor for type 2 diabetes mellitus and CVD. Additionally, we suggest how metabolic syndrome might be useful in clinical practice, especially for the prediction of diabetes. (J Diabetes Invest,
INTRODUCTION
The clustering of glucose intolerance, hypertension, dyslipidemia and obesity, particularly central obesity, has been termed metabolic syndrome [1] [2] [3] . Ever since metabolic syndrome was described by Reaven 4 in 1988, various definitions have been published and revised, and numerous studies have explored its pathophysiology. When the concept of metabolic syndrome was first proposed, the primary pathological process was believed to be insulin resistance or hyperinsulinemia [5] [6] [7] [8] . In addition, many etiological factors have been linked to the development and progression of metabolic syndrome, including an altered inflammatory state 9, 10 , visceral adipose tissue abnormalities 11 , and the activation of the sympathetic nervous system 12 
.
Although metabolic syndrome contains several unresolved matters, including ambiguous criteria, the inclusion of diabetes, a unifying mechanism and its role as a 'syndrome' 13 , its worldwide prevalence has increased rapidly into one of the biggest health problems. Metabolic syndrome is known to increase cardiovascular morbidity and mortality, type 2 diabetes, and all-cause mortality 14 . The desired clinical response to metabolic syndrome is improved individual and national public health, and a mitigation of negative outcomes through comprehensive management.
Most studies agree that cardiovascular disease (CVD) is the major outcome of metabolic syndrome [15] [16] [17] . However, whether type 2 diabetes mellitus is also a major outcome of metabolic syndrome or one of its components is a topic of debate. Many reports have confirmed a strong relationship between metabolic syndrome and incident diabetes.
The present review describes various definitions and changes in the prevalence of the metabolic syndrome, and the significance of metabolic syndrome as a risk factor of type 2 diabetes mellitus and CVD. Finally, we propose the clinical usefulness inherent to metabolic syndrome, especially as a predictor of incident diabetes.
VARIOUS DEFINITIONS OF THE METABOLIC SYNDROME Although most medical communities agree that obesity, hypertension, dyslipidemia and abnormal glucose tolerance should be factored into the diagnosis, no standard criteria have been set for metabolic syndrome. Several clinical definitions have been proposed and used in clinical practice ( Table 1) .
The first formalized definition of metabolic syndrome was introduced in 1998 by a group who was consulted by the World Health Organization (WHO) for a definition of diabetes 1 . The diagnostic criteria included markers of abnormal glucose metabolism or insulin resistance, plus at least two out of four risk factors, which included obesity, hypertension, elevated triglycerides and/or reduced high-density lipoprotein (HDL) cholesterol, and microalbuminuria. Insulin resistance, as measured by the homeostasis model assessment of insulin resistance (HOMA-IR) 18 also emphasized the presence of insulin resistance. In the three aforementioned definitions listed, both impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) were noted as markers of abnormal glucose metabolism. However, in contrast to the WHO definition, patients with type 2 diabetes were not included in the EGIR and AACE criteria.
The most commonly used criteria emerged from the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) in 2001 3 . The presence of three of the five risk factors warrants a metabolic syndrome diagnosis. Under the direction of the American Diabetes Association (ADA), the definition of dysglycemic factor was changed from a fasting plasma glucose (FPG) higher than 110 mg/dL in 2001 to a FPG higher than 100 mg/dL in 2006 19 . The International Diabetes Federation (IDF), American Heart Association (AHA), and National Heart, Lung, and Blood Institute (NHLBI) define metabolic syndrome as central obesity based on waist circumference plus two or more additional metabolic risk factors 20, 21 . Central obesity criteria were revised in 2005 and 2009; they applied different classification criteria based on ethnicity and risk factor status of CVD. Type 2 diabetes is included; however, the IGT criteria are not in NCEP or IDF. These approaches possess the strength of simplicity and the practicality of their components. In contrast, these approaches are limited, because they underestimate the prevalence of IGT and insulin resistance 14 .
PREVALENCE OF METABOLIC SYNDROME
The worldwide prevalence of metabolic syndrome is increasing. In the USA, age-adjusted prevalence increased from 29.2% in the National Health and Nutrition Examination Survey (NHANES) III to 34.2% in NHANES 1999 34.2% in NHANES -2006 . Prevalence is significantly higher in women, especially younger women aged 20-39 years. This increasing trend has been observed in Asian countries as well. Age-adjusted prevalence in the South Korea NHANES (KNHANES) 1998 was 24.9%, and increased to 31.3% in the KNHANES 2007 with the application of revised NCEP criteria 23 . Distinct and rapid increases in prevalence occur in women aged at least 50 years, after menopause, whereas metabolic syndrome in men aged at least 60 years decreases gradually; and the prevalence in adolescents increased from 6.8% in KNHANES 1998 to 9.2% in KNHANES 2001 24 , to 13.0% in KNHANES 2005 25 . In China, the prevalence of metabolic syndrome increased persistently as well 26 . Variance in the prevalence is a result of the use of differing criteria and inclusion of different ethnicities. In a meta-analysis in 2007, Nestel et al. 27 reported prevalence ranges of 10-30% in several Asian countries, including South Korea, China, Singapore, Taiwan, Hong Kong and the Philippines. For Japan, the diagnostic criteria for central obesity differ from other Asian countries, with waist circumference measurements of more than 85 cm for males and 90 cm for females. Based on this definition, prevalence was 22.8% for men and 8.7% for women in the Japanese National Health and Nutrition Survey (NHNS) 2003 28 . However, when other criteria were applied (waist circumference ‡85 cm for males and ‡ 80 cm for females), the prevalence in females was increased from 8. METABOLIC SYNDROME AS A PREDICTOR OF CVD Numerous studies have confirmed the prognostic significance of metabolic syndrome on cardiovascular outcomes, including some negative results ( Table 2) .
The results of the Botnia study on 4,483 middle-aged participants in Finland and Sweden showed a marked increase in cardiovascular mortality in participants with metabolic syndrome during a 6.9-year follow-up period (12.0 vs 2.2%, P < 0.001) 15 . In the Kuopio Ischemic Heart Disease Risk Factor Study, metabolic syndrome was associated with a 2.5 to 2.8-fold greater risk of death from any cardiovascular cause 29 . However, the relative risks (RR) and statistical significance varied with differing definitions of metabolic syndrome. The RR associated with WHO definitions was significant in all adjustment models; however, when the NCEP criteria (waist circumference over 94 cm) were used, no statistical significance was found in the association between RR and CVD mortality after adjustment for conventional risk factors, such as age, examination year, low-density lipoprotein (LDL) cholesterol, smoking status and family history of coronary heart disease. A meta-analysis on the 87 studies that used NCEP or revised NCEP definitions confirmed that metabolic syndrome is associated with a twofold increase in cardiovascular outcomes 17 . 30, 31 . The Hisayama Study, 14-year prospective study that 30 . CVD predictability tended to vary by sex and numbers of components [31] [32] [33] . Wilson et al. 32 determined that the RR of coronary heart diseases was significantly higher in women than in men, although they did share the same number of metabolic risk factors. In that study, the presence of three or more metabolic risk factors increased the risk for coronary heart diseases (CHD) 2.5-fold in men and approximately sixfold in women during the 16-year follow-up period of middle-aged adults. In the presence of two risk factors, the RR was approximately 2.0 in men and 3.0 in women. A study of 2,435 Korean participants (age range 20-78 years) showed that the odds ratios (OR) for CVD were higher in women (OR 4.04; 95% CI 1.78-9.14) than in men (OR 1.98; 95% CI 1.30-3.03) 31 . In the Beaver Dam Study, the incidence of CVD was 2.5% in a group to have 0 components of the metabolic syndrome by WHO definition and 14.9% in four more risk factors 16 . METABOLIC SYNDROME AS A PREDICTOR OF TYPE 2 DIABETES Many large-scale clinical trials and meta-analyses reported that the presence of metabolic syndrome, regardless of definition, was highly predictive of new-onset type 2 diabetes in many different populations (Table 3 ). Some studies showed that the RR for incident diabetes is higher than it is for CVD 34 . Based on a meta-analysis of 42,419 participants from 16 cohorts, the average estimated RR for incident diabetes was 3.5-5.2, and did not differ appreciably with each definition. In contrast, the RR for CVD was 1.5-2.0 34 . The Insulin Resistance Atherosclerosis Study (IRAS) showed that the OR for diabetes development based on the NCEP and IDF definitions was similar to the WHO definition, despite the use of modified risk factors 35 . The study of Aboriginal Canadians showed a prevalence of diabetes three to fivefold higher than in non-Aboriginal Canadians, and metabolic syndrome had associated with incident diabetes regardless of the use of the NCEP criteria (OR 2.03; 95% CI 1.1-3.75) or IDF criteria (OR 2.14; 95% CI 1.29-3.55) to define metabolic syndrome 36 . In contrast, Cameron et al. 37 reported a higher OR for the WHO criteria (OR 4.6; 95% CI 3.5-6.0) compared with EGIR criteria (OR 3.2; 95% CI 2.3-4.3), NCEP criteria (OR 3.1; 95% CI 2.3-4.0) and IDF criteria (OR 3.0; 95% CI 2.2-4.2). In addition, the OR for incident diabetes in a study of 4,756 Iranian subjects was highest using the WHO criteria (OR 11.0; 95% CI 7.9-15.3) during the 3.6-year follow-up period 38 . In that study, the OR using the IDF criteria was 4.3 (95% CI 3.0-6.0), the original NCEP criteria (FPG ‡ 110 mg/ dL) was 3.7 (95% CI 2.7-5.1), and using modified NCEP criteria (FPG ‡ 100 mg/dL) was 4.9 (95% CI 3.5-6.9). According to a meta-analysis carried out by Ford et al.
34
, the random-effects summary RR was 5 To test which criteria enable improved predictability for the development of diabetes, we reviewed several statistical analyses that varied according to sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs) and the area under the receiver operating characteristics curve (aROC). The sensitivity ranged from 0.224 to 0.722, and the specificity ranged from 0.613 to 0.939 [37] [38] [39] [40] [41] [42] [43] . PPVs ranged from 0.078 to 0.36 and NPVs ranged from 0.90 to 0983 [37] [38] [39] [40] [41] [42] . A factor analysis study of 1,918 Pima Indians confirmed that the WHO definition led to superior sensitivity and specificity compared with the NCEP definition, because the former weights the presence of insulin resistance 43 . Also, in a longitudinal survey of 3, 198 Mauritius subjects, the WHO definitions resulted in a higher value of sensitivity (42.1%) and PPV (26.8%) compared with the IDF and NCEP definitions 37 . However, differences among the aROCs (range 0.68-0.86) were small and insignificant, despite the differing criteria 14, 35, 39, [44] [45] [46] . The predictability of metabolic syndrome for incident diabetes was superior to the predictability associated with either the Framingham Risk Score (FRS) 47 or classical clinical risk factors excluding laboratory parameters, such as FPG, triglyceride, HDL-cholesterol and blood pressure 33 . Several studies examined that the number of metabolic syndrome components associated with the risk of type 2 diabetes 16, 33, [47] [48] [49] . According to a substudy on 3,323 members of the Framingham Heart Study Offspring Study, the RR for type 2 diabetes had increased with the number of metabolic syndrome components when the NECP criteria were applied 33 . The adjusted RR for participants with three abnormalities or four more abnormalities was 4.56 (95% CI 2.48-8.78) and 10.88 (95% CI 5.77-20.50), respectively, in the British Regional Heart study 47 . In the West of Scotland Coronary Prevention study, Sattar et al. 48 used the NCEP definition based on body mass index (BMI) instead of waist circumference, with or without the inclusion of C-reactive protein (CRP). The estimated RR for participants with three abnormalities or four more abnormalities was 7.26 (95% CI 2.25-23.40) and 24.4 (95% CI 7.53-79.6). In the Beaver Dam study, Klein et al. 16 used a modified WHO definition to determine that the OR for the incidence of diabetes was 9.37 (95% CI 2.22-39.59) in the group with three abnormalities and 33.67 (95% CI 7.93-142.96) in the group with four or more abnormalities. Another study that was not based on one of the major definitions also reported that the RR relates to three or more risk factors 49 . Among the components of metabolic syndrome, IFG has been shown as the strongest predictor for type 2 diabetes development 37, [40] [41] [42] 50 . Subjects with metabolic syndrome, which included the IFG trait, showed a RR of 11.0 (95% CI 8.1-14.9), whereas the RR for subjects excluding IFG were 5.0 (95% CI 3.7-6.8) in the Framingham Offspring Study 33 . Lorenzo et al. 41 showed that the OR of incidental diabetes was 5.03 (95% CI 3.39-7.48) in participants with metabolic syndrome excluding IFG, 7.07 (95% CI 3.32-15.1) in participants without metabolic syndrome including IFG, and 21.0 (95% CI 13.1-33. . In a recently published study on older populations in Finland, the HR of each metabolic syndrome component for the development of type 2 diabetes was 1.75 (95% CI 1.04-2.95) for the obesity factor, 1.34 (95% CI 0.78-2.31) for the triglyceride factor, 1.60 (95% CI 0.91-2.81) for the HDL-cholesterol factor, 1.87 (95% CI 0.45-7.76) for the blood pressure factor and 5.16 (95% CI 2.68-9.93) for the IFG factor 51 . The strong relationship between metabolic syndrome with IFG and incident type 2 diabetes mellitus was not predictive of CVD. Whether other components (except for FPG) are related to incident diabetes remains controversial. Hwang et al. 31 reported that a dramatic decrease in the risk of incident diabetes was observed in men after the initial FPG was 20, 53, 54 . However, more research is required to confirm the validity of these new markers.
CLINICAL INTERPRETATIONS OF METABOLIC SYNDROME Some concern has emerged with regard to the lack of certainty inherent to metabolic syndrome, its pathogenesis and its value as a risk marker of CVD 13 . Nevertheless, the syndrome is used widely and conveniently in clinical practice and research fields; an important aspect of its clinical significance is the 'visualization' of the risk for CVD and type 2 diabetes development. By receiving a diagnosis of metabolic syndrome, patients might become motivated to actively carry out lifestyle modifications, and physicians can implement the focused risk management and comprehensive implementation approaches available to them to mitigate major complications.
The debate has continued on the inclusion of type 2 diabetes mellitus in definitions of metabolic syndrome (Figure 1 ) 55 . Early detection of individuals at high risk for type 2 diabetes is essential not only for the prevention of diabetes itself, but also to decrease associated cardiovascular complications. As aforementioned, metabolic syndrome is ideal as a predictor of incident diabetes. With the inclusion of diabetes in the defining criteria, metabolic syndrome loses its clinical advantage as a predictor for the development of diabetes. In addition, physicians should not expect effects from concurrent prevention measures for incident type 2 diabetes and its complications to overlap with active intervention of metabolic syndrome. Therefore, heavy consideration should be given to the exclusion of diabetes from the definition, and more focus should fall on the role of metabolic syndrome as an intervention tool for diabetes prevention.
Among the five components of metabolic syndrome, IFG is particularly superior for its ability to predict incident diabetes 33, 41, 51 ; the other components can predict CVD better than or similarly to IFG 33 . Thus, metabolic syndrome with IFG is complimentary, allowing the prediction of CVD and diabetes; the populations in this group require extra care in management.
The role of metabolic syndrome in patients who have been diagnosed with diabetes is a topic many believe should not be ignored. Alexander et al. 55 reported that in the USA, over 80% of participants aged 50 years or older with diabetes also have metabolic syndrome. Most patients with type 2 diabetes possess multiple risk factors for CVD other than hyperglycemia. Because CVD is the leading cause of death in diabetic patients 56, 57 , careful attention should be exercised with regard to all modifiable risk factors. Many clinical studies have confirmed that adequate control of blood pressure and lipid profiles can reduce cardiovascular risk effectively [58] [59] [60] . However, diabetes itself is a strong risk factor for CVD, and type 2 diabetes mellitus is well-known for its similar risks to coronary heart disease 61 . Consequently, the value of metabolic syndrome in diabetic patients is relatively weak compared with its value in non-diabetic subjects.
In conclusion, metabolic syndrome is immensely useful as a clinical tool to predict diabetes and CVD, especially in high-risk groups with metabolic syndrome that includes IFG. Exclusion of diabetes mellitus in metabolic syndrome is important to maximize the prevention effect of CVD with preceding diabetes mellitus. Further studies are required in several areas, including unified classification, ambiguous pathogenesis, the 'syndrome' role and the development of a more effective model. 
